Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol-Induced Liver Damage.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
03
08
2021
received:
27
05
2021
accepted:
04
08
2021
pubmed:
24
11
2021
medline:
3
5
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
Alcoholic fatty liver disease (AFLD) is characterized by lipid accumulation and inflammation and can progress to cirrhosis and cancer in the liver. AFLD diagnosis currently relies on histological analysis of liver biopsies. Early detection permits interventions that would prevent progression to cirrhosis or later stages of the disease. Herein, we have conducted the first comprehensive time-course study of lipids using novel state-of-the art lipidomics methods in plasma and liver in the early stages of a mouse model of AFLD, i.e., Lieber-DeCarli diet model. In ethanol-treated mice, changes in liver tissue included up-regulation of triglycerides (TGs) and oxidized TGs and down-regulation of phosphatidylcholine, lysophosphatidylcholine, and 20-22-carbon-containing lipid-mediator precursors. An increase in oxidized TGs preceded histological signs of early AFLD, i.e., steatosis, with these changes observed in both the liver and plasma. The major lipid classes dysregulated by ethanol play important roles in hepatic inflammation, steatosis, and oxidative damage. Conclusion: Alcohol consumption alters the liver lipidome before overt histological markers of early AFLD. This introduces the exciting possibility that specific lipids may serve as earlier biomarkers of AFLD than those currently being used.
Identifiants
pubmed: 34811964
doi: 10.1002/hep4.1825
pmc: PMC8870008
pii: 02009842-202203000-00009
doi:
Substances chimiques
Biomarkers
0
Triglycerides
0
Ethanol
3K9958V90M
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-525Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK048520
Pays : United States
Organisme : NIAAA NIH HHS
ID : R21 AA028432
Pays : United States
Organisme : NIAAA NIH HHS
ID : R24 AA022057
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.
Références
Ten Hove M, Pater L, Storm G, Weiskirchen S, Weiskirchen R, Lammers T, et al. The hepatic lipidome: from basic science to clinical translation. Adv Drug Deliv Rev 2020;159:180‐197.
Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006;290:G852‐G858.
World Health Organization . Global status report on alcohol and health 2018. https://www.who.int/publications‐detail‐redirect/9789241565639 . Published September 27, 2018. Accessed May 2021.
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749‐1761.
Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12‐month alcohol use, high‐risk drinking, and DSM‐IV alcohol use disorder in the United States, 2001‐2002 to 2012‐2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017;74:911‐923.
Arab JP, Roblero JP, Altamirano J, Bessone F, Chaves Araujo R, Higuera‐De la Tijera F, et al. Alcohol‐related liver disease: clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). Ann Hepatol 2019;18:518‐535.
Dugum M, McCullough A. Diagnosis and management of alcoholic liver disease. J Clin Transl Hepatol 2015;3:109‐116.
Argemi J, Ventura‐Cots M, Rachakonda V, Bataller R. Alcoholic‐related liver disease: pathogenesis, management and future therapeutic developments. Rev Esp Enferm Dig 2020;112:869‐878.
Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911‐917.
Koelmel JP, Kroeger NM, Gill EL, Ulmer CZ, Bowden JA, Patterson RE, et al. Expanding lipidome coverage using LC‐MS/MS data‐dependent acquisition with automated exclusion list generation. J Am Soc Mass Spectrom 2017;28:908‐917.
Koelmel J, Sartain M, Salcedo J, Murali A, Li X, Stow S & Improving coverage of the plasma lipidome using iterative MS/MS data acquisition combined with lipid annotator software and 6546 LC/Q‐TOF. Published June 30, 2020. https://www.agilent.com/cs/library/applications/application‐6546‐q‐tof‐lipidome‐5994‐0775en‐agilent.pdf. Accessed May 2021.
Koelmel JP, Kroeger NM, Ulmer CZ, Bowden JA, Patterson RE, Cochran JA, et al. LipidMatch: an automated workflow for rule‐based lipid identification using untargeted high‐resolution tandem mass spectrometry data. BMC Bioinformatics 2017;18:331.
Koelmel JP, Cochran JA, Ulmer CZ, Levy AJ, Patterson RE, Olsen BC, et al. Software tool for internal standard based normalization of lipids, and effect of data‐processing strategies on resulting values. BMC Bioinformatics 2019;20:217.
Koelmel JP, Aristizabal‐Henao JJ, Ni Z, Fedorova M, Kato S, Otoki Y, et al. A novel technique for redox lipidomics using mass spectrometry: application on vegetable oils used to fry potatoes. J Am Soc Mass Spectrom 2021;32:1798‐1809.
Ivanova PT, Milne SB, Myers DS, Brown HA. Lipidomics: a mass spectrometry based systems level analysis of cellular lipids. Curr Opin Chem Biol 2009;13:526‐531.
Bowden JA, Heckert A, Ulmer CZ, Jones CM, Koelmel JP, Abdullah L, et al. Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950‐metabolites in frozen human plasma. J Lipid Res 2017;58:2275‐2288.
Lanaspa MA, Andres‐Hernando A, Orlicky DJ, Cicerchi C, Jang C, Li N, et al. Ketohexokinase C blockade ameliorates fructose‐induced metabolic dysfunction in fructose‐sensitive mice. J Clin Invest 2018;128:2226‐2238.
Clugston RD, Gao MA, Blaner WS. The hepatic lipidome: a gateway to understanding the pathogenes is of alcohol‐induced fatty liver. Curr Mol Pharmacol 2017;10:195‐206.
Wang Z, Yao T, Song Z. Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. J Lipid Res 2010;51:3158‐3165.
Zerbino DR, Achuthan P, Akanni W, Amode M, Barrell D, Bhai J, et al. Ensembl 2018. Nucleic Acids Res 2018;46:D754‐D761.
Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014;510:58‐67.
Harizi H, Corcuff J‐B, Gualde N. Arachidonic‐acid‐derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008;14:461‐469.
Clugston RD, Jiang H, Lee MX, Piantedosi R, Yuen JJ, Ramakrishnan R, et al. Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. J Lipid Res 2011;52:2021‐2031.
Yang L, Jin G‐H, Zhou J‐Y. The role of ceramide in the pathogenesis of alcoholic liver disease. Alcohol Alcohol 2016;51:251‐257. https://doi.org/10.1093/alcalc/agv119 .
doi: 10.1093/alcalc/agv119
Liangpunsakul S, Sozio MS, Shin E, Zhao Z, Xu Y, Ross RA, et al. Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through elevated ceramide levels. Am J Physiol Gastrointest Liver Physiol 2010;298:G1004‐G1012.
You M, Matsumoto M, Pacold CM, Cho WK, Crabb DW. The role of AMP‐activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004;127:1798‐1808.
Van de Wiel A. The effect of alcohol on postprandial and fasting triglycerides. Int J Vasc Med 2012;2012:862504.
Bennett M, Gilroy DW. Lipid mediators in inflammation. Microbiol Spectr 2016;4.
González‐Périz A, Planagumà A, Gronert K, Miquel R, López‐Parra M, Titos E, et al. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S‐hydroxy‐DHA. FASEB J 2006;20:2537‐2539.
Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, et al. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006;3:321‐331.
Smith TL, Vickers A. Increases in liver microsomal phosphatidylethanolamine methyltransferase activity(s) in mice after short‐term ethanol treatments. Subst Alcohol Actions Misuse 1984;5:131‐140.
Morand OH, Zoeller RA, Raetz CR. Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation. J Biol Chem 1988;263:11597‐11606.
Skaff O, Pattison DI, Davies MJ. The vinyl ether linkages of plasmalogens are favored targets for myeloperoxidase‐derived oxidants: a kinetic study. Biochemistry 2008;47:8237‐8245.
Ikuta A, Sakurai T, Nishimukai M, Takahashi Y, Nagasaka A, Hui S‐P, et al. Composition of plasmalogens in serum lipoproteins from patients with non‐alcoholic steatohepatitis and their susceptibility to oxidation. Clin Chim Acta 2019;493:1‐7.
Jang JE, Park H‐S, Yoo HJ, Baek I‐J, Yoon JE, Ko MS, et al. Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice. Hepatology 2017;66:416‐431. Erratum in: Hepatology 2019;70:453.
Hauck AK, Bernlohr DA. Oxidative stress and lipotoxicity. J Lipid Res 2016;57:1976‐1986.
Siler SQ, Neese RA, Hellerstein MK. De novo lipogenesis, lipid kinetics, and whole‐body lipid balances in humans after acute alcohol consumption. Am J Clin Nutr 1999;70:928‐936.
You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: role of sterol regulatory element‐binding proteins. Alcohol 2004;34:39‐43.
Rasineni K, Casey CA. Molecular mechanism of alcoholic fatty liver. Indian J Pharmacol 2012;44:299‐303.
Régnier M, Polizzi A, Guillou H, Loiseau N. Sphingolipid metabolism in non‐alcoholic fatty liver diseases. Biochimie 2019;159:9‐22.
Feldstein AE, Lopez R, Tamimi TAR, Yerian L, Chung Y‐M, Berk M, et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010;51:3046‐3054.